DCS Surgical is a medical device startup developing a minimally invasive surgical procedure for sinusitis. The company is based in Boulder, Colorado, and is currently in stealth mode.

DNAtrix is a biotech company commercializing an oncolytic virus therapy for glioblastoma, an aggressive form of brain cancer, with founders from the University of Texas M.D. Anderson Cancer Center and the University of California San Francisco Cancer Center. DNAtrix began its human clinical trials in early 2009.

GlycosBio is transforming the fuels and chemicals industries with biological systems that can flexibly manufacture high value products from a wide range of non-food feedstocks.  The company has acquired and developed a platform technology that enables low cost production of chemicals with environmentally friendly technologies as an alternative to petrochemical-based manufacturing. Products envisioned include replacement of existing polymers with chemically equivalent polymers entirely derived from renewable resources.

Imagnx, Inc. is a next-generation, magnetic resonance imaging (MRI) company focusing on disease-specific MR imaging for cancer, Alzheimer’s and other CNS degenerative diseases. The Company is in the process of commercializing major university and research center technology, based on non-toxic and non-radioactive isotopes. Imagnx is currently in stealth mode.

Marval Biosciences develops novel CT contrast agents that reduce toxicity to patients and improve imaging performance. These next-generation contrast agents will enable a much broader population of patients to use CT for diagnosis of cardiovascular diseases without fear of contrast-induced nephropathy, which can cause acute kidney failure, particularly in elderly and diabetic patients. Based in Houston, Texas, Marval was created through the licensing of intellectual property from the University of Texas Health Science Center at Houston, Georgia Institute of Technology, Case Western Reserve University, Cleveland State University and The University of Houston.

Prolacta Bioscience is a life sciences company that is dedicated to improving quality of life by Advancing the Science of Human Milk™. Prolacta creates specialty preparations made from human milk, therefore containing purely human protein, for the nutritional needs of premature and critically ill infants in neo-natal intensive care units (NICUs). The company is the sole provider of a human milk fortifier made from 100% human milk, ProlactPlus H2MF. Prolacta operates a pharmaceutical grade processing plant and has designed and patented processes unique to the science of human milk. Prolacta is committed to supporting research in the areas of human milk and premature infant nutrition in order to assist health care professionals in providing the best possible care for the most fragile babies.

Swift Biosciences is developing molecular biology reagents for research and diagnostic applications. Swift’s products help users detect genes and gene products that other products can’t. The company’s products also help users to analyze their samples faster, at higher volume, and at a lower price-per-sample. Swift’s products are designed to be compatible with customers’ current instrumentation.

Vertos Medical has commercialized an innovative, percutaneous treatment for lumbar spinal stenosis (LSS). LSS is a painful and debilitating condition diagnosed in more than 1.5 million people each year in the U.S. The Vertos MILD (Minimally Invasive Lumbar Decompression) procedure can be performed under local anesthesia and substantially reduces the costs and risks associated with other minimally invasive or open surgeries.